Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRP3 in clopidogrel resistance
ChiCTR-OCH-14004382Phase 4Recruiting
- Sponsor
- Nanjing First Hospital
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of clopidogrel in coronary arteriosclerosis, sponsored by Nanjing First Hospital. Primary endpoint: Inhibition of platelet aggregation. Started Apr 2014; status: recruiting.
02
Drugs
clopidogrel
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR-OCH-14004382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OCH-14004382.